Characteristics of imatinib treated PR-2 group compared with GR. (A) The line plot indicates BCR::ABL1% dynamics for PR-1, PR-2, and GR groups. The median BCR::ABL1% at each time point per group was plotted, and the line was fitted by using generalized additive mode smoothing. The shaded gray area for each line indicates 95% confidence intervals. (B) Box plot shows the 3-months BCR::ABL1% halving time (days) in patients treated with imatinib in PR-1, PR-2, and GR groups. (C) Box plot shows the 6-months BCR::ABL1% halving time (days) in PR-1, PR-2 and GR imatinib treated patient groups. (D) Bar plot shows the proportion of inferior achievement of MMR (BCR::ABL1 <0.1% [IS]) at 12 months in patients treated with imatinib classified by PR-1, PR-2, and GR. (E) Volcano plot shows Hallmark pathways that associated with PR-2 when compared with GR based on gene-set enrichment analysis.